公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study | CHIUN-SHENG HUANG ; Yu A.L.; Tseng L.-M.; Chow L.W.C.; Hou M.-F.; Hurvitz S.A.; Schwab R.B.; L Murray J.; Chang H.-K.; Chang H.-T.; Chen S.-C.; Kim S.-B.; Hung J.-T.; Ueng S.-H.; Lee S.-H.; Chen C.-C.; Rugo H.S. | Journal for immunotherapy of cancer | 30 | 27 | |
2017 | Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial | Kim S.-B.; Maslyar D.J.; Dent R.; Im S.-A.; Espi? M.; Blau S.; Tan A.R.; Isakoff S.J.; Oliveira M.; Saura C.; Wongchenko M.J.; Kapp A.V.; Chan W.Y.; Singel S.M.; Baselga J.; Kim S.-B.; Lee K.S.; Im S.-A.; Espi? M.; Wang H.-C.; Blau S.; Dent R.; Tan A.; Sohn J.H.; De Laurentiis M.; Estevez L.G.; CHIUN-SHENG HUANG ; Romieu G.; Velez M.; Villanueva R.; Conte P.F.; Dakhil S.; Debled M.; Martin A.G.; Hurvitz S.; Kim J.H.; Levy C.; Oliveira M.; Rovira P.S.; Seo J.H.; Valero V.; Vidal G.; Wong A.; Allison M.A.K.; Figlin R.; Chan D.; Chen S.-C.; Chen Y.-H.; Cobleigh M.; De Braud F.; Dirix L.; Hansen V.; Bessard A.H.; Iannotti N.; Isakoff S.; Lawler W.; Monta?o A.; Salkini M.; Seigel L.; on behalf of the, LOTUS investigators, LOTUS investigators | The Lancet Oncology | 376 | 338 | |
2014 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | De Azambuja E.; Holmes A.P.; Piccart-Gebhart M.; Holmes E.; Di Cosimo S.; Swaby R.F.; Untch M.; Jackisch C.; Lang I.; Smith I.; Boyle F.; Xu B.; Barrios C.H.; Perez E.A.; Azim H.A.; Kim S.-B.; Kuemmel S.; CHIUN-SHENG HUANG ; Vuylsteke P.; Hsieh R.-K.; Gorbunova V.; Eniu A.; Dreosti L.; Tavartkiladze N.; Gelber R.D.; Eidtmann H.; Baselga J. | The Lancet Oncology | 387 | 330 | |
2020 | Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial | Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU ; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators | Journal of Clinical Oncology | 360 | 311 | |
2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y. | The Lancet Oncology | 722 | 630 | |
2018 | Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial | Bardia A.; Parton M.; Kummel S.; Estevez L.G.; CHIUN-SHENG HUANG ; Cortes J.; Ruiz-Borrego M.; Telli M.L.; Martin-Martorell P.; Lopez R.; Beck J.T.; Ismail-Khan R.; Chen S.-C.; Hurvitz S.A.; Mayer I.A.; Carreon D.; Cameron S.; Liao S.; Baselga J.; Kim S.-B. | Journal of Clinical Oncology | 39 | 37 | |
2013 | Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial | Azim H.A.; Agbor-Tarh D.; Bradbury I.; Dinh P.; Baselga J.; Di Cosimo S.; Greger Jr. J.G.; Smith I.; Jackisch C.; Kim S.-B.; Aktas B.; CHIUN-SHENG HUANG ; Vuylsteke P.; Hsieh R.K.; Dreosti L.; Eidtmann H.; Piccart M.; De Azambuja E. | Journal of Clinical Oncology | 48 | 47 | |
2022 | A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer | Kuemmel S.; Campone M.; Loirat D.; Lopez R.L.; Thaddeus Beck J.; de Laurentiis M.; Im S.-A.; Kim S.-B.; Kwong A.; Steger G.G.; Adelantado E.Z.; Duhoux F.P.; Greil R.; Kuter I.; YEN-SHEN LU ; Tibau A.; ?zg?ro?lu M.; Scholz C.W.; Singer C.F.; Vega E.; Wimberger P.; Zamagni C.; Couillebault X.-M.; Fan L.; Guerreiro N.; Mataraza J.; Sand-Dejmek J.; Chan A. | Clinical Cancer Research | 15 | 15 | |
2020 | Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer | Kojima T.; Shah M.A.; Muro K.; Francois E.; Adenis A.; CHIH-HUNG HSU ; Doi T.; Moriwaki T.; Kim S.-B.; Lee S.-H.; Bennouna J.; Kato K.; Shen L.; Enzinger P.; Qin S.-K.; Ferreira P.; Chen J.; Girotto G.; de la Fouchardiere C.; Senellart H.; Al-Rajabi R.; Lordick F.; Wang R.; Suryawanshi S.; Bhagia P.; Peter Kang S.; Metges J.-P.; KEYNOTE-181 Investigators | Journal of Clinical Oncology | 592 | 495 | |
2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | Okada M.; Kato K.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Matsumura Y.; Takazawa A.; Kitagawa Y. | Clinical Cancer Research | 18 | 16 | |